OMALIZUMAB
omalizumab 75 mg/0.5 mL injection, 0.5 mL syringe
OMALIZUMAB (11958J)
11958J
Manner of administration:Injection
Restriction
Indication: Uncontrolled severe allergic asthma
Treatment phase: Initial treatment - Initial 1 (New patient; or Recommencement of treatment in a new
treatment cycle following a break in PBS-subsidised biological medicine therapy),
Initial treatment - Initial 2 (Change of treatment), Continuing treatment - Balance
of Supply in a patient aged 6 to 12 years
